Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin (Q46113172)

19 December 2017

title

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin (English)

1 reference

19 December 2017

1 reference

metastatic colon cancer

1 reference

1 reference

Tony R Reid

1

1 reference

19 December 2017

Scott Freeman

2

1 reference

19 December 2017

Leonard Post

3

1 reference

19 December 2017

Frank McCormick

4

1 reference

19 December 2017

Daniel Y Sze

5

1 reference

19 December 2017

publication date

1 August 2005

1 reference

19 December 2017

published in

Cancer Gene Therapy

1 reference

19 December 2017

volume

12

1 reference

19 December 2017

issue

8

1 reference

19 December 2017

page(s)

673-681

1 reference

19 December 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

The role of irinotecan in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Treatment of colon and rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

An update on hepatic arterial infusion chemotherapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

ONYX-015 selectivity and the p14ARF pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Developments in medical oncology and their implications for interventional radiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

inferred from DOI database lookup

7 January 2021

based on heuristic

Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

inferred from DOI database lookup

7 January 2021

based on heuristic

Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700819

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.CGT.7700819

1 reference

19 December 2017

1 reference

19 December 2017